Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
Johnson & Johnson reaches deal with US government to lower drug prices
08:43pm, Thursday, 08'th Jan 2026
Johnson & Johnson said on Thursday it has reached a agreement with U.S. President Donald Trump's administration to cut drug prices for Americans in exchange for exemptions from U.S. tariffs.
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare's leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the
J&J's Innovative Medicine Segment in Q4: Here's What to Watch
10:01am, Thursday, 08'th Jan 2026
JNJ's Innovative Medicine segment shows resilience ahead of Q4 results, with key drugs driving growth despite Stelara biosimilars and Part D headwinds.
Daymark Wealth Partners LLC Has $39.44 Million Position in Johnson & Johnson $JNJ
05:38am, Thursday, 08'th Jan 2026
Daymark Wealth Partners LLC lifted its stake in Johnson and Johnson (NYSE: JNJ) by 6.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. T
CWA Asset Management Group LLC Sells 21,081 Shares of Johnson & Johnson $JNJ
05:38am, Thursday, 08'th Jan 2026
CWA Asset Management Group LLC decreased its holdings in Johnson and Johnson (NYSE: JNJ) by 17.4% during the undefined quarter, according to the company in its most recent filing with the SEC. The ins
Johnson & Johnson $JNJ Shares Acquired by D.A. Davidson & CO.
04:52am, Thursday, 08'th Jan 2026
D.A. Davidson and CO. lifted its stake in shares of Johnson and Johnson (NYSE: JNJ) by 1.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exc
JNJ's Nipocalimab Meets Goal in Phase II Study for Systemic Lupus
12:50pm, Wednesday, 07'th Jan 2026
J&J's phase IIb JASMINE study on nipocalimab meets key endpoints in systemic lupus erythematosus, supporting plans to advance the drug into phase III.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:55am, Wednesday, 07'th Jan 2026
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration
08:00am, Wednesday, 07'th Jan 2026
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced that the company has submitted the OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration (FDA) in an applic
The Smartest Dividend Stocks to Buy With $3,000 Right Now
03:35am, Wednesday, 07'th Jan 2026
Contrary to a common assumption, McDonald's main business isn't as a fast-food restaurant chain. After a lengthy dry spell, Johnson & Johnson is starting to fire on all cylinders again.
Asset Management One Co. Ltd. Buys 47,524 Shares of Johnson & Johnson $JNJ
03:29am, Wednesday, 07'th Jan 2026
Asset Management One Co. Ltd. grew its stake in shares of Johnson and Johnson (NYSE: JNJ) by 3.9% in the undefined quarter, according to its most recent disclosure with the SEC. The institutional inve
JNJ vs. AZN: Which Drug Stock Comes Out on Top for Investors?
12:55pm, Tuesday, 06'th Jan 2026
J&J's diversified pharma and MedTech strength stacks up against AstraZeneca's oncology-led growth as investors weigh stability versus faster expansion.
The JASMINE study met the primary endpoint and key secondary and exploratory endpoints, including those indicating the potential of nipocalimab for steroid sparing SLE is one of the most prevalent and
Novel immunotherapy combination regimen brings together two complementary therapies to improve outcomes for people living with multiple myeloma as early as second line1
Forget Venezuela Hype: Jim Cramer Explains Why You Missed Oil Trade And What Stocks To Buy Instead
06:13am, Tuesday, 06'th Jan 2026
Jim Cramer warns against the Venezuela oil trade. Find out which undervalued bank and pharma stocks he says to buy for 2026 instead.
